No company can match StemCyte's LifeSaver Guarantee!
With StemCyte's Hybrid model you will naturally
receive support and options at NO additional cost
If for any reason your newborn's cord blood unit fails to engraft, StemCyte's LifeSaver Guarantee will:
-
Find a replacement at no cost to parents from StemCyte's public inventory.
-
Refund All Fees.
-
Provide parents with an additional $50k.
Cord Blood & Tissue Banking
Cord Blood & Tissue Banking
Cord Blood & Tissue Banking
MaxCell®
Annual Cord Blood Plans
FDA Approved Treatments
Cord Blood Stem Cells
FDA Approved Treatments
Cord Blood Stem Cells
Cord Blood Cord blood contains a rich source of various cells including hematopoietic stem cells which form blood cells. Today, there are 80 diseases that can be treated with cord blood stem cells. Also, there are more than 100 active cord blood stem cell clinical trials worldwide investigating the treatment of various diseases like autism.
An Overview
StemCyte's Top Advantages
There are many important things to consider before choosing a company to preserve your newborn's cord blood and cord tissue. As pioneers in regenerative medicine, StemCyte knows what truly matters at every step of banking. We hope this list of our top advantages will give you the confidence in our science, products, and the people who will care for your family's future health and well-being.
An Overview
StemCyte's Top Advantages
There are many important things to consider before choosing a company to preserve your newborn's cord blood and cord tissue. As pioneers in regenerative medicine, StemCyte knows what truly matters at every step of banking. We hope this list of our top advantages will give you the confidence in our science, products, and the people who will care for your family's future health and well-being.
Cord Blood & Cord Tissue Preservation
(866) 389-4659
The Pioneer in Regenerative Medicine
Cord Blood & Cord Tissue Banking
Learn why StemCyte has been the trusted leader around the world in Regenerative Medicine for 23+ years! Our goal is to consistently support the advancement of cord blood and cord tissue stem cell transplants and therapies, and deliver life-changing solutions to families around the world.
1997
StemCyte was founded with a mission to advance the racial diversity of stem cell donations and storage and to increase global stem cell research.
2000
Two StemCyte locations were in full operation and increasing its global inventory.
2001
Singapore's Dr. Patrick Tan performed the world's first successful cord blood transplant for thalassemia major, and subsequently received a President's Award for his efforts.
2003
StemCyte received AABB banking accreditation in the USA and Taiwan.
The world’s first Umbilical Cord Blood Transplantation Symposium was hosted by StemCyte at City of Hope National Cancer Hospital in Los Angeles, California.
2005
StemCyte launched its private banking divisions in the USA and Taiwan.
StemCyte Taiwan received the world’s first grant for a non-US public bank and approval
from the Taiwan Food and Drug Administration (TFDA) for a Phase II IND clinical trial testing 12 patients diagnosed with Beta-Thalassemia Major.
StemCyte USA received a US Congressional earmark to diversify the United States' public cord bank inventory.
2006
Dr. Wise Young, (Rutgers University) partnered with StemCyte to conduct clinical trials with the Company's newly-launched advanced therapeutics division.
StemCyte is the world’s first cord blood bank to receive accreditation for Allogeneic and Autologous banking from the Foundation for the Accreditation of Cellular Therapy (FACT).
StemCyte is the first private cord blood bank to become a Health Resources and Services Administration (HRSA) partner.
2008
StemCyte expanded its operations to India and partnered with The Apollo Hospital Group and Cadila Pharmaceutical.
A US patent was submitted for stem cell brain damage treatments.
2010
Two clinical trials were conducted:
-
The first, chronic stroke patients using autologous peripheral blood stem cells (CD34+). This trial had an 85% success rate.
-
The second was for the treatment of spinal cord injuries using mononuclear cells from HLA matched CBU from StemCyte’s inventory.
StemCyte applied for a method patent for the modification of cord blood stem cells that are resistant to HIV.
2011
StemCyte and Dr. Young collaborated for a phase II spinal cord injury treatment.
StemCyte USA was awarded a U.S. Patent for its unique Plasma Depletion UCB Processing method.
A cord blood collection partnership was established between StemCyte and Sharp Healthcare in San Diego, California
2012
The second phase of Dr. Young's spinal cord injury treatment was completed in 2012.
StemCyte received TFDA approval for its Phase II IND clinical trial using CD34+ from patients' peripheral blood for chronic stroke treatment.
During this year, a Chinese patent for the use of Lithium + UCB was awarded to StemCyte.
UC Davis and StemCyte partnered and developed a public cord blood bank program.
2013
Kaiser and StemCyte partnered to create an innovative model for cord blood collection.
StemCyte applied for a US patent through partner Cell Research Corporation for storing and expanding mesenchymal and epithelial cells for therapeutic products.
2015
StemCyte reached a significant milestone by shipping its 2,000th transplant unit.
StemCyte relocated to a new state-of-the-art facility in Baldwin Park, California.
StemCyte received a patent for Lithium Stimulation of Stem Cells Proliferation and growth factor production.
2016
StemCyte was awarded a Japanese patent for stem cell screening of HIV infection.
2018
StemCyte is the first hybrid cord blood bank to receive FDA approval for a Phase II clinical trial to treat spinal cord injuries.
StemCyte sponsored a Phase I Clinical Trial using cord blood stem cells to treat acute ischemic stroke.
2021+
Stay Tuned...
The Future is So Bright
with StemCyte